/ Print /

Health/Disease Strategy

Four oncology treatment advances to watch
Four oncology treatment advances to watchExperts say a cancer care revolution is here. Here’s a closer look at some advancements in cancer treatments to watch.
Genetic testing: 3 things managed healthcare executives should knowA new survey on genetic testing has surprisingly results on consumer acceptance and impact for healthcare executives.
Here’s a more effective way to test for HPVA Kaiser Permanente study found that a new way to test for HPV has the potential to increase efficiency and decrease waste.
‘Encouraging’ COPD drug pipeline could ease symptoms, address root causesAlbert A. Rizzo, MD, senior medical advisor for the American Lung Association, says the increasing number of drugs in the pipeline could improve airflow address the underlying disease process.
Don’t let your tools to curb the opioid epidemic go to wasteNew public opinion survey about opioid use from Prime Therapeutics has surprising results.
Unique payer-provider cancer treatment partnershipsUnique partnerships between payers and providers focus on keeping patients out of the hospital and on the road to remission.
Managing cancer treatment side effects: What payers should knowMoffitt Cancer Center expert shares her thinking on managing chemotherapy-related side effects.
COPD patient education needs, challenges: What health execs should knowEducation is a significant element of comprehensive care for COPD patients. In this Q&A, one expert shares her recommendations.
Potential CVS-Aetna merger: Top 6 industry implicationsHealthcare executives identify how the industry could be affected if the Aetna-CVS merger goes through.
Potential CVS-Aetna merger: Key takeaways for health execsThe CVS Health-Aetna potential merger will have healthcare executives rethinking traditional industry competitors. Here’s why.